Willgoss, Tom
Escontrias, Omar A.
Scrafton, Carole
Oehrlein, Elisabeth
Livingstone, Victoria
Chaplin, Fiona C.
Benivento, Maddalena
Chapman, Hayley
Brooke, Nicholas
Funding for this research was provided by:
Patient Focused Medicines Development
Article History
Received: 5 May 2023
Accepted: 2 October 2023
First Online: 12 October 2023
Declarations
:
: At the start of the public consultation, before any responses were submitted, all participants were informed about the nature of the data collection. All data collected from respondents was not personally identifiable. Participants were further informed that no data would be shared with the public, that any information collected would be kept confidential, and that it would only be shared with and used by the PFMD project team to improve the current project. They were also informed that all responses would be aggregated to provide a picture of how this work is perceived and might be used in communications as part of measuring the outcomes of this work.
: Not applicable.
: EO is employed by Applied Patient Experience, LLC, which has contracts with a variety of non-profit organizations, pharmaceutical companies, and academic institutions. OAE is the Senior Vice President, Equity, Research and Programs at the National Health Council, a non-profit, membership organization that receives dues, sponsorships, and grants; a complete list of members, sponsors, and funders is available on the National Health Council website. However, both EO and OAE declare they have no conflicts of interest with this work and that none of the activities or sponsorship listed would have influenced the work reported. All other authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this article.